What Is SLU-PP-332?
SLU-PP-332 research has emerged at the frontier of exercise biology and metabolic science, with this small molecule ERR agonist demonstrating the remarkable ability to activate the full transcriptional program of aerobic exercise adaptation in skeletal muscle — producing mitochondrial biogenesis, oxidative fiber type shifts, and endurance capacity improvements in preclinical models without physical activity.
SLU-PP-332 is a synthetic small molecule agonist of estrogen-related receptors alpha and gamma (ERRα and ERRγ) — two closely related orphan nuclear receptors that function as master transcriptional regulators of mitochondrial biogenesis, oxidative metabolism, and exercise-adaptive gene expression. Developed at Washington University School of Medicine by Thomas Bhatt and colleagues, SLU-PP-332 was identified through a screen for compounds capable of activating ERRα/γ-dependent transcriptional programs. Unlike earlier ERR modulators, SLU-PP-332 demonstrates sufficient potency and selectivity to produce robust in vivo metabolic effects following systemic administration — making it a practical research tool for investigating ERR biology and exercise mimicry in animal models. Its molecular weight is approximately 432 Da.
Mechanism of Action
ERRα and ERRγ Agonism
Estrogen-related receptors alpha and gamma are orphan nuclear receptors — transcription factors that structurally resemble estrogen receptors but have no known endogenous ligand. They constitutively occupy and activate gene promoters containing estrogen response element-related sequences, and their activity is regulated primarily through coactivator recruitment rather than classical ligand-dependent activation. ERRα and ERRγ are among the most potent activators of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) target genes — the master regulator of mitochondrial biogenesis — and SLU-PP-332’s agonism amplifies this transcriptional activity beyond constitutive ERR levels.
PGC-1α Pathway Activation and Mitochondrial Biogenesis
PGC-1α is the primary transcriptional coactivator driving mitochondrial biogenesis — the process by which cells increase their mitochondrial content in response to energy demands, including endurance exercise. PGC-1α activity drives expression of nuclear-encoded mitochondrial proteins, mitochondrial transcription factor A (TFAM) for mitochondrial DNA replication and transcription, and components of all five electron transport chain complexes. Research has demonstrated that SLU-PP-332 activates PGC-1α-dependent gene programs in skeletal muscle — increasing mitochondrial density, oxidative phosphorylation capacity, and the expression of oxidative metabolic enzymes — essentially replicating the transcriptional response to endurance exercise training.
Oxidative Fiber Type Shifting
Skeletal muscle fibers exist on a spectrum from fast-twitch glycolytic (Type IIb) to slow-twitch oxidative (Type I) — with endurance training driving fiber type shifting toward the oxidative end of the spectrum. This shift involves increased mitochondrial content, upregulation of oxidative enzyme expression, myosin heavy chain isoform changes, and enhanced fatty acid oxidation capacity. Research has demonstrated that SLU-PP-332 treatment produces fiber type shifting in skeletal muscle consistent with the adaptations of endurance training — increasing the proportion of oxidative fiber characteristics without physical exercise.
Fatty Acid Oxidation Enhancement
ERRα and ERRγ directly regulate the transcription of genes involved in fatty acid uptake (CD36, FABP), mitochondrial fatty acid import (CPT1, ACSL), and beta-oxidation enzyme expression. SLU-PP-332 agonism upregulates this entire fatty acid oxidation gene program — shifting substrate utilization from glucose toward fat and increasing the cell’s capacity to oxidize fatty acids for ATP production. This metabolic flexibility enhancement is a key feature of aerobic exercise adaptation and has implications for metabolic disease research involving excess lipid accumulation in muscle, liver, and adipose tissue.
Cardiac Metabolism Modulation
ERRα is the dominant transcriptional regulator of cardiac energy metabolism — controlling the expression of genes responsible for fatty acid oxidation, glucose oxidation, and mitochondrial ATP production in cardiomyocytes. The adult heart derives approximately 70% of its ATP from fatty acid oxidation under normal conditions, and this metabolic preference is maintained by ERRα. Research has examined SLU-PP-332’s effects on cardiac metabolism and function in models of heart failure, where pathological metabolic remodeling toward glucose dependence (the “fetal gene program”) impairs cardiac energetics.
Research Applications
Exercise Mimicry and Metabolic Research
The most extensively discussed application for SLU-PP-332 concerns exercise mimicry — the pharmacological reproduction of exercise-induced metabolic adaptations in the absence of physical activity. Research has demonstrated improvements in endurance capacity, mitochondrial density, and oxidative metabolism in SLU-PP-332-treated mice — with treated animals running significantly longer on treadmill endurance tests compared to controls without exercise training. These results position SLU-PP-332 as a research tool for understanding the molecular mechanisms of exercise adaptation, and for investigating whether pharmacological exercise mimicry can confer metabolic benefits in models of exercise intolerance.
Metabolic Disease Research
Skeletal muscle mitochondrial dysfunction and impaired fatty acid oxidation are central features of insulin resistance, obesity, and type 2 diabetes. Research has examined SLU-PP-332’s ability to improve metabolic outcomes in diet-induced obesity and insulin resistance models — investigating whether ERRα/γ-driven mitochondrial enhancement and fat oxidation promotion can improve glucose homeostasis, reduce ectopic lipid accumulation, and restore metabolic flexibility in compromised metabolic states.
Cardiac Research
Heart failure is characterized by pathological metabolic remodeling — a shift from fatty acid oxidation toward glucose dependence that reduces cardiac energetic efficiency and contributes to contractile dysfunction. Research has examined whether SLU-PP-332’s ERRα agonism can prevent or reverse this metabolic remodeling in heart failure models, potentially improving cardiac energetics and function through restoration of normal oxidative metabolism.
Sarcopenia and Aging Muscle Research
Age-related skeletal muscle loss (sarcopenia) is accompanied by reductions in muscle mitochondrial content, oxidative enzyme activity, and physical performance — changes that parallel the reductions in exercise capacity seen in sedentary aging. Research has examined SLU-PP-332’s ability to partially restore mitochondrial function and exercise capacity in aged muscle models — investigating whether pharmacological ERR agonism can attenuate sarcopenia-related mitochondrial decline.
Neurological and Cognitive Research
Exercise produces well-documented cognitive benefits through multiple mechanisms including BDNF upregulation, neurogenesis promotion, and improved cerebral blood flow. Research has begun examining whether SLU-PP-332-induced exercise-mimetic metabolic changes extend to the CNS — investigating effects on brain mitochondrial function, BDNF expression, and cognitive performance metrics in preclinical models.
SLU-PP-332 in the AminoForge Metabolic Research Catalog
SLU-PP-332 is one of the most novel exercise mimetic compounds currently available for research. At AminoForge, researchers investigating metabolic biology and mitochondrial function may find it most productive when studied alongside complementary metabolic compounds: MOTS-C — a mitochondria-derived peptide that activates AMPK through a distinct mechanism (folate cycle-AICAR pathway) and drives complementary exercise-adaptive gene programs — and 5-Amino-1MQ, an NNMT inhibitor studied for fat cell metabolism and energy expenditure. For broader metabolic research combining GLP-1 pathway and mitochondrial mechanisms, GLP-1(R) offers complementary appetite and glucose regulation mechanisms. For further reading see: SLU-PP-332 ERR agonism and exercise-mimetic effects in skeletal muscle (PubMed).
Shop SLU-PP-332 at AminoForge — ≥99% purity, third-party COA verified, USA manufactured, ships within 48 hours.
Formulation and Storage
SLU-PP-332 is available as a lyophilized powder. As a small molecule (approximately 432 Da) rather than a peptide, SLU-PP-332 has different solubility and stability properties from most research peptides — it is sparingly soluble in water and may require DMSO or other organic solvents for initial dissolution before aqueous dilution. Standard storage at −20°C for lyophilized powder applies, with protection from moisture and light. Research-grade purity should be verified at ≥99% by HPLC with mass spectrometry confirmation of the correct molecular weight prior to use.
All products sold by AminoForge are intended exclusively for laboratory and research purposes. Not for human or veterinary consumption. Researchers are responsible for compliance with all applicable laws and regulations governing research compound use in their jurisdiction.